Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treat...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546519/ https://www.ncbi.nlm.nih.gov/pubmed/28108743 http://dx.doi.org/10.18632/oncotarget.14735 |
_version_ | 1783255566097842176 |
---|---|
author | Bighin, Claudia Dozin, Beatrice Poggio, Francesca Ceppi, Marcello Bruzzi, Paolo D’Alonzo, Alessia Levaggi, Alessia Giraudi, Sara Lambertini, Matteo Miglietta, Loredana Vaglica, Marina Fontana, Vincenzo Iacono, Giuseppina Pronzato, Paolo Mastro, Lucia Del |
author_facet | Bighin, Claudia Dozin, Beatrice Poggio, Francesca Ceppi, Marcello Bruzzi, Paolo D’Alonzo, Alessia Levaggi, Alessia Giraudi, Sara Lambertini, Matteo Miglietta, Loredana Vaglica, Marina Fontana, Vincenzo Iacono, Giuseppina Pronzato, Paolo Mastro, Lucia Del |
author_sort | Bighin, Claudia |
collection | PubMed |
description | Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treatment: chemotherapy or hormonal-therapy. Outcomes in terms of clinical benefit and median overall survival (OS) were retrospectively evaluated in the two groups. To calculate the time spent in chemotherapy with respect to OS in the two groups, the proportion of patients in chemotherapy relative to those present in either group was computed at every day from the start of therapy. Results From 1999 to 2013, 119 patients received first-line hormonal-therapy (HT-first group) and 100 first-line chemotherapy (CT-first group). Patients in the CT-first group were younger and with poorer prognostic factors as compared to those in HT-first group. Clinical benefit (77 vs 81%) and median OS (50.7 vs 51.1 months) were similar in the two groups. Time spent in chemotherapy was significantly longer during the first 3 years in CT-first group (54-34%) as compared to the HT-first group (11-18%). This difference decreased after the third year and overall was 28% in the CT-first group and 18% in the HT-first group. Conclusions The sequence first-line chemotherapy followed by hormonal-therapy, as compared with the opposite sequence, is associated with a longer time of OS spent in chemotherapy. However, despite the poorer prognostic factors, patients in the CT-first group had a superimposable OS than those in the HT-first group. |
format | Online Article Text |
id | pubmed-5546519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55465192017-08-23 Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study Bighin, Claudia Dozin, Beatrice Poggio, Francesca Ceppi, Marcello Bruzzi, Paolo D’Alonzo, Alessia Levaggi, Alessia Giraudi, Sara Lambertini, Matteo Miglietta, Loredana Vaglica, Marina Fontana, Vincenzo Iacono, Giuseppina Pronzato, Paolo Mastro, Lucia Del Oncotarget Clinical Research Paper Introduction Although hormonal-therapy is the preferred first-line treatment for hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical trials support the choice between hormonal-therapy and chemotherapy. Methods Patients were divided into two groups according to the treatment: chemotherapy or hormonal-therapy. Outcomes in terms of clinical benefit and median overall survival (OS) were retrospectively evaluated in the two groups. To calculate the time spent in chemotherapy with respect to OS in the two groups, the proportion of patients in chemotherapy relative to those present in either group was computed at every day from the start of therapy. Results From 1999 to 2013, 119 patients received first-line hormonal-therapy (HT-first group) and 100 first-line chemotherapy (CT-first group). Patients in the CT-first group were younger and with poorer prognostic factors as compared to those in HT-first group. Clinical benefit (77 vs 81%) and median OS (50.7 vs 51.1 months) were similar in the two groups. Time spent in chemotherapy was significantly longer during the first 3 years in CT-first group (54-34%) as compared to the HT-first group (11-18%). This difference decreased after the third year and overall was 28% in the CT-first group and 18% in the HT-first group. Conclusions The sequence first-line chemotherapy followed by hormonal-therapy, as compared with the opposite sequence, is associated with a longer time of OS spent in chemotherapy. However, despite the poorer prognostic factors, patients in the CT-first group had a superimposable OS than those in the HT-first group. Impact Journals LLC 2017-01-18 /pmc/articles/PMC5546519/ /pubmed/28108743 http://dx.doi.org/10.18632/oncotarget.14735 Text en Copyright: © 2017 Bighin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Bighin, Claudia Dozin, Beatrice Poggio, Francesca Ceppi, Marcello Bruzzi, Paolo D’Alonzo, Alessia Levaggi, Alessia Giraudi, Sara Lambertini, Matteo Miglietta, Loredana Vaglica, Marina Fontana, Vincenzo Iacono, Giuseppina Pronzato, Paolo Mastro, Lucia Del Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title_full | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title_fullStr | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title_full_unstemmed | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title_short | Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
title_sort | hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546519/ https://www.ncbi.nlm.nih.gov/pubmed/28108743 http://dx.doi.org/10.18632/oncotarget.14735 |
work_keys_str_mv | AT bighinclaudia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT dozinbeatrice hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT poggiofrancesca hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT ceppimarcello hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT bruzzipaolo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT dalonzoalessia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT levaggialessia hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT giraudisara hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT lambertinimatteo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT migliettaloredana hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT vaglicamarina hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT fontanavincenzo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT iaconogiuseppina hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT pronzatopaolo hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy AT mastroluciadel hormonaltherapyfollowedbychemotherapyorthereversesequenceasfirstlinetreatmentofhormoneresponsivehumanepidermalgrowthfactorreceptor2negativemetastaticbreastcancerpatientsresultsofanobservationalstudy |